Authors: De Santis M et al, ASCO 2010 Abstract: LBA4519 Reviewed by: Dr. Lori Wood

www.OncologyEducation.ca

Randomized phase II/III trial comparing gemcitabine/ carboplatin (GC) and methotrexate/carboplatin/

vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based

chemotherapy (CHT): Phase III results of EORTC study 30986

Authors: De Santis M et al, ASCO 2010Abstract: LBA4519Reviewed by: Dr. Lori WoodDate posted: Jun 18 2010

www.OncologyEducation.ca

Thank you for downloading this update. Please feel free to use it for educational purposes.

Please acknowledge OncologyEducation.ca and Dr. Wood when using these slides.

www.OncologyEducation.ca

STUDY RATIONALE

• Up to 50% of pateints with metastatic urothelial cancer are not eligible for standard dose cisplatin due to creatinine clearance, performance status, and co-morbidities

• Difficult to know how to treat unfit patients with metastatic urothelial cancer

• Also, there is no clear consensus on how to define “unfit”– For this study: based on ECOG PS and GFR

www.OncologyEducation.ca

R

Treatment A: M-CAVI:Methotrexate 30 mg/m2 d1, d15, d22Carboplatin AUC 4.5 d1Vinblastine 3 mg/m2 d1, d15, d22q4wksN=119

Treatment B: GC:Gemcitabine 1000 mg/m2 d1 and d8Carboplatin AUC 4.5 d1q3wksN=119

STUDY DESIGN

- Metastatic TCC- Unfit patients: - PS 2 and/or - GFR 30-60 ml/min- Primary outcome: - overall survival- Statistics: - median OS 9.0m 13.5m with GC

www.OncologyEducation.ca

RESULTS

GC MCAVI HR P valuePS 0

1

2

16.8%

38.7%

44.5%

16%

38.7%

45.4%

Visceral Metastases 46.2% 55.5% SS

GFR 60 ml/min 55% 55%

RECIST RR 41.2% 30.3% p=0.01

PFS 5.8m 4.2m p=0.78

OS 9.3m 8.1m 0.94 p=0.64

Median follow-up = 4.5 years

www.OncologyEducation.ca

RESULTS: TOXICITY

GC MCAVI P value

Grade 3/4 Thrombocytopenia 48.3% 19.4% SS

Febrile Neutropenia 4.2% 14.4% SS

Severe/Acute Toxicity

(predefined definition)9.3% 21.2% SS

www.OncologyEducation.ca

STUDY COMMENTARY

• Gemcitabine/Carboplatin did not increase overall survival compared to Methotrexate, Carboplatin, Vinblastine

• It was somewhat more tolerable

www.OncologyEducation.ca

BOTTOM-LINE FOR CANADIAN MEDICAL ONCOLOGISTS

• Most Canadian medical oncologists would not be using Methotrexate, Carboplatin and Vinblastine as their standard therapy for unfit patients

• Most would be using:– Gemcitabine alone– Gemcitabine/Carboplatin

• This trial supports the use of Gem/Carbo given that it does not have a worse outcome and does have a better tolerability

• This trial also gives a modern day median survival for unfit bladder cancer patients based on the Bajorin (MSKCC) risk factors (poor PS and presence of visceral metastases)– 0 factors = 12m– 1 factor = 9.3m – 2 factors = 5.5m